Latest News

Stefanie Köhler  (Credit: LinkedIn)
Survey Study Aims to Assess Germany’s Readiness for Early Alzheimer Diagnosis Using Biomarkers

April 3rd 2025

A new survey study will assess how well German memory clinics and specialists are equipped to provide early and accurate Alzheimer diagnoses using biomarker-based methods.

Cognito’s Gamma Sensory Stimulation Leads to Preserved Corpus Callosum Structure in Alzheimer Disease
Cognito’s Gamma Sensory Stimulation Leads to Preserved Corpus Callosum Structure in Alzheimer Disease

April 3rd 2025

Beyond CSF: Quanterix’s Simoa Platform Brings Blood-Based Biomarkers to the Forefront
Beyond CSF: Quanterix’s Simoa Platform Brings Blood-Based Biomarkers to the Forefront

April 3rd 2025

Sarepta’s Duchenne Gene Therapy Trials Paused in Europe Amid Patient Death Investigation
Sarepta’s Duchenne Gene Therapy Trials Paused in Europe Amid Patient Death Investigation

April 3rd 2025

Patient-Informed Phase 2 ATLANTIS Study Tests Selective D1PAM Agent Glovadalen for Parkinson Disease
Patient-Informed Phase 2 ATLANTIS Study Tests Selective D1PAM Agent Glovadalen for Parkinson Disease

April 3rd 2025

Coverage of the 2025 MDA Clinical & Scientific Conference

Get direct access to interviews with experts, as well as the latest data and clinical news updates, straight from the conference floor in Dallas, Texas.

MDA 2025

Conference Coverage

View All
Stefanie Köhler  (Credit: LinkedIn)
Survey Study Aims to Assess Germany’s Readiness for Early Alzheimer Diagnosis Using Biomarkers

April 3rd 2025

Cognito’s Gamma Sensory Stimulation Leads to Preserved Corpus Callosum Structure in Alzheimer Disease
Cognito’s Gamma Sensory Stimulation Leads to Preserved Corpus Callosum Structure in Alzheimer Disease

April 3rd 2025

Beyond CSF: Quanterix’s Simoa Platform Brings Blood-Based Biomarkers to the Forefront
Beyond CSF: Quanterix’s Simoa Platform Brings Blood-Based Biomarkers to the Forefront

April 3rd 2025

Assessing Investigational CT1812’s Impact on Tau, Amyloid, and Neurodegeneration: Mary Hamby, PhD
Assessing Investigational CT1812’s Impact on Tau, Amyloid, and Neurodegeneration: Mary Hamby, PhD

April 3rd 2025

Video Series
Video Interviews
Podcasts

Most Recent

© 2025 MJH Life Sciences

All rights reserved.